FR177391, a new anti-hyperlipidemic agent from Serratia: II. Pharmacological activity of FR177391

Journal of Antibiotics

Volumn 58, Issue 10, 2005, Pages 640-647

  Inami, Masamichi ^a   Kawamura, Ikuo ^a   Tsujimoto, Susumu ^a   Yasuno, Tohru ^a   Lacey, Elizabeth ^a   Hirosumi, Jiro ^a   Takakura, Shoji ^a   Nishigaki, Fusako ^a   Naoe, Yoshinori ^a   Manda, Toshitaka ^a   Mutoh, Seitaro ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

FR177391; Hypertriglyceridemia; Lipoprotein lipase activator

Indexed keywords

ANTILIPEMIC AGENT; FR 177391; FRUCTOSE; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; NATURAL PRODUCT; TRIACYLGLYCEROL; TYLOXAPOL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG ISOLATION; ENZYME ACTIVITY; ENZYME RELEASE; EPIDIDYMIS FAT; HYPERTRIGLYCERIDEMIA; INOCULATION; INSULIN RESISTANCE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SERRATIA LIQUEFACIENS; TREATMENT OUTCOME;

ANIMALIA; MURINAE; SERRATIA; SERRATIA LIQUEFACIENS;

EID: 28244479462     PISSN: 00218820     EISSN: None     Source Type: Journal    
DOI: 10.1038/ja.2005.88     Document Type: Article

References (26)

1. Sato B, Nakajima H, Fujita T, Takase S, Yoshimura S, Kinoshita T, Terano H. FR177391, a new lipoprotein lipase activating agent from Serratia. I. Taxonomy, fermentation, isolation, physico-chemical properties, structure elucidation and biological activities. J Antibiot 58: 634-639 (2005)
2. Hauner H, Entenmann G, Wabitsch M, Gaillard D, Ailhaud G, Negrel R, Pfeiffer EF. Promoting effect of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium. J Clin Invest 84: 1663-1670 (1989)
3. Tsutsumi K, Inoue Y, Shima A, Iwasaki K, Kawamura M, Murase T. The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis. J Clin Invest 92: 411-417 (1993)
4. Tsutsumi K, Inoue Y, Shima A, Murase T. Correction of hypertriglyceridemia with low high-density lipoprotein cholesterol by the novel compound NO-1886, a lipoprotein lipase-promoting agent, in STZ-induced diabetic rats. Diabetes 44: 414-417 (1995)
5. Tsutsumi K, Inoue Y, Hagi A, Murase T. The novel compound NO-1886 elevates plasma high-density lipoprotein cholesterol levels in hamsters and rabbits by increasing lipoprotein lipase activity without any effect on cholesteryl ester transfer protein activity. Metabolism 46: 257-260 (1997)
6. Chiba T, Miura S, Sawamura F, Uetsuka R, Tomita I, Inoue Y, Tsutsumi K, Tomita T. Antiatherogenic effects of a novel lipoprotein lipase-enhancing agent in cholesterol-fed New Zealand white rabbits. Atheroscler Thromb Vasc Biol 17: 2601-2608 (1997)
7. Tsutsumi K, Inoue Y, Murase T. Effects of NO-1886, a lipoprotein lipase promoting agent, on homozygous and heterozygous Watanabe heritable hyperlipidaemic rabbits. Arzneim-Forsch Drug Res 50: 118-121 (2000)
8. Nilsson-Ehle P, Schotz MC. A stable, radioactive substrate emulsion for assay of lipoprotein lipase. J Lipid Res 17: 536-541 (1976)
9. Otway S, Robinson DS. The use of a non-ionic detergent (Triton WR1339) to determine rates of triglyceride entry into the circulation of the rat under different physiological conditions. J Physiol 190: 321-332 (1967)
10. Ishikawa T, Fidge N. Changes in the concentration of plasma lipoproteins and apoproteins following the administration of Triton WR 1339 to rats. J Lipid Res 20: 254-264 (1979)
11. Sleder J, Chen YDI, Cully MD, Reaven GM. Hyperinsulinemia in fructose-induced hypertriglyceridemia in the rat. Metabolism 29: 303-305 (1980)
12. Zavaroni I, Sander S, Scott S, Reaven GM. Effect of fructose feeding on insulin secretion and insulin action in the rat. Metabolism 29: 970-973 (1980)
13. Hwang IS, Ho H, Hoffman BB, Reaven GM. Fructose-induced insulin resistance and hypertension in rats. Hypertension 10: 512-516 (1987)
14. Zavaroni I, Chen YDI, Reaven GM. Studies of the mechanism of fructose-induced hypertriglyceridemia in the rat. Metabolism 31: 1077-1083 (1982)
15. Kobayashi K, Forte TM, Taniguchi S, Ishida BY, Oka K, Chan L. The db/db mouse, a model for diabetic dyslipidemia: molecular characterization and effects of western diet feeding. Metabolism 49: 22-31 (2000)
16. Tsujimoto S, Kawamura I, Inami M, Lacey E, Nishigaki F, Naoe Y, Manda Y, Goto T. Cachexia induction by EL-4 lymphoma in mice and possible involvement of impaired lipoprotein lipase activity. Anticancer Res 20: 3111-3116 (2000)
17. 2-like particles during lipolysis of very low density lipoproteins in vitro. Proc Natl Acad Sci USA 75: 4519-4523 (1978)
18. Chung BH, Segrest JP. Cytotoxicity of remnants of triglyceride-rich lipoproteins: an atherogenic insult? Adv Exp Med Biol 285: 341-351 (1991)
19. Weinstock PH, Bisgaier CL, Aalto-Setala K, Radner H, Ramakrishnan R, Levak-Frank S, Essenburg AD, Zechner R, Breslow JL. Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes. J Clin Invest 96: 2555-2568 (1995)
20. Shimada M, Shimano H, Gotoda K, Yamamoto K, Kawamura M, Inaba T, Yazaki Y, Yamada N. Overexpression of human lipoprotein lipase in transgenic mice. Resistance to diet-induced hypertriglyceridemia and hypercholesterolemia. J Biol Chem 268: 17924-17929 (1993)
21. Hara T, Cameron-Smith D, Cooney GJ, Kusunoki M, Tsutsumi K, Storlien LH. The actions of a novel lipoprotein lipase activator, NO-1886, in hypertriglyceridemic fructose-fed rats. Metabolism 47: 149-153 (1998)
22. Malloy MJ, Kane JP. A risk factor for atherosclerosis: triglyceride-rich lipoproteins. Adv Intern Med 47: 111-136 (2001)
23. Rapp RJ. Hypertriglyceridemia: a review beyond low-density lipoprotein. Cardiol Rev 10: 163-172 (2002)
24. Szapary PO, Rader DJ. Pharmacological management of high triglycerides and low high-density lipoprotein cholesterol. Curr Opin Pharmacol 1: 113-120 (2001)
25. Rader DJ, Haffner SM. Role of fibrates in the management of hypertriglyceridemia. Am J Cardiol 83: 30F-35F (1999)
26. Breuer HW. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin. Curr Med Res Opin 17: 60-73 (2001)